A pharmacokinetic study of adriamycin and 4′epi-adriamycin after simultaneous intra-arterial liver administration
The plasma pharmacokinetics of adriamycin and 4′epi-adriamycin were studied in patients with malignant tumors of the liver after simultaneous regional administration of equal amounts of the two anthracyclines by the arterial route. The use of a highly selective liquid chromatographic analytical method permitted quantification of plasma concentrations of the two drugs as well as their corresponding 13-hydroxy metabolites.
The plasma concentrations of each drug followed a three-compartment open model. On average the area under the plasma concentration time curve (AUC) and the maximum plasma concentration (C max) were 2.1 and 1.7 times larger for adriamycin than for 4′epi-adriamycin, respectively. 4′Epi-adriamycin was eliminated faster than adriamycin, the terminal half-life time being on the average 1.5 times higher for adriamycin. These findings are in agreement with what has previously been observed after intravenous administration.
The plasma concentrations of the 13-hydroxy metabolites did not exceed 30 ng ml−1. The AUC values of these metabolites were on average 20% of the AUC values of the intact drugs.
Key wordsAnthraquinone glycosides Adriamycin Epirubicin Pharmacokinetics Chemotherapy Intraarterial Liver cancer
Unable to display preview. Download preview PDF.
- 2.Mattsson W, Jonsson K, Hellekant C, Hallsten L: Short-term intra-arterial Mitomycin C in hepatic metastases.Acta Radiol 19, 321 (1980).Google Scholar
- 11.Hurteloup P, Cappelaere P, Armand J P, Mathé G: Phase II clinical evaluation of 4′-epi-doxorubicin.Cancer Treatment Rep 67, 337 (1983).Google Scholar
- 12.Naguse N, Yukaya H, Suehiro S: Intra-arterial administration of 4′-epi-adriamycin in the treatment of hepatocellular carcinoma.Proc 2nd Int Workshop for Chemotherapy of Hepatic Tumors, Sendai, 28 September, pp. 76–85 (1983).Google Scholar
- 13.Kuroda C, Okamura J, Tanaka T, Tokunaga K, Hori S, Yoshioka H, Sakurai M: Effect of transcatheter intra-arterial infusion of 4′epi-adriamycin in a case of hepatocellular carcinoma with tumor thrombi in the portal vein.Proc 2nd Int Workshop for Chemotherapy of Hepatic Tumors, Sendai, 28 September, pp. 86–92 (1983).Google Scholar
- 17.Gibaldi M, Perrier D:Pharmacokinetics. New York, Marcel Dekker (1975).Google Scholar
- 20.Camaggi C M, Strocchi E, Tamassia V, Martoni A, Giovannini M, Iafelice G, Canova N, Marraro D, Martini A, Pannuti F: Pharmacokinetic studies of 4′-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.Cancer Treatment Rep 66, 1819 (1982).Google Scholar
- 22.Martini A, Moro E, Pacciarini M A, Tamassia V, Natale N, Piazza E: Cross-over study of pharmacokinetics and haematological toxicity of 4′-epi-doxorubicin and doxorubicin in cancer patients.Int J Clin Pharmac Res 4, 231 (1984).Google Scholar
- 23.Natale N, Piazza E, Italia C, Trabattoni A, Luchini S: The kinetics of anthracyclines in human plasma and tissues: daunomycin, doxorubicin and 4′epi-doxorubicin.Drugs Exp Clin Res 9, 775 (1983).Google Scholar
- 24.Robert J, Vrignaud P, Nguyen-Ngoc T, Illiadis A, Mauriac L, Hurteloup P: Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.Cancer Treatment Rep 69, 633 (1985).Google Scholar
- 25.Eksborg S, Stendahl U, Lönroth U: A comparative pharmacokinetic study of adriamycin and 4′epi-adriamycin after simultaneous intravenous administration.Eur J Clin Pharmac (in press).Google Scholar
- 27.Takanashi S, Bachur N R: Adriamycin metabolism man: evidence from urinary metabolites.Drug Met Disp 4, 79 (1976).Google Scholar
- 28.Bachur N R: Adriamycin (NSC-123127) pharmacology.Cancer Chemother Rep, Part 3 6, 153 (1975).Google Scholar